• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ERCC1 as Predictor of Platinum Benefit in Non-Small-Cell Lung Cancer.

作者信息

Postel-Vinay Sophie, Soria Jean-Charles

机构信息

Sophie Postel-Vinay and Jean-Charles Soria, Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Paris-Saclay University, and INSERM, UMR981, Villejuif, France.

出版信息

J Clin Oncol. 2017 Feb;35(4):384-386. doi: 10.1200/JCO.2016.70.5053. Epub 2016 Nov 28.

DOI:10.1200/JCO.2016.70.5053
PMID:27893323
Abstract
摘要

相似文献

1
ERCC1 as Predictor of Platinum Benefit in Non-Small-Cell Lung Cancer.ERCC1作为非小细胞肺癌铂类获益预测指标
J Clin Oncol. 2017 Feb;35(4):384-386. doi: 10.1200/JCO.2016.70.5053. Epub 2016 Nov 28.
2
ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.ERCC1基因单核苷酸多态性作为接受铂类化疗的非小细胞肺癌患者潜在的预测生物标志物
Cancer Invest. 2015 Apr;33(4):107-13. doi: 10.3109/07357907.2014.1001897. Epub 2015 Feb 3.
3
Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer.两种 ERCC1 抗体作为早期非小细胞肺癌预后和预测生物标志物的比较。
Anticancer Res. 2014 Jul;34(7):3707-13.
4
ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.在晚期非小细胞肺癌中，ERCC1信使核糖核酸表达与铂类化疗方案后的反应和生存情况无关。
J Thorac Oncol. 2007 Oct;2(10):902-6. doi: 10.1097/JTO.0b013e318155a637.
5
The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis.铂类药物治疗晚期非小细胞肺癌，低/阴性 ERCC1 表达是否优于高/阳性 ERCC1 表达？一项荟萃分析。
Lung Cancer. 2010 Oct;70(1):63-70. doi: 10.1016/j.lungcan.2010.05.010. Epub 2010 Jun 11.
6
Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.APE1、BRCA1、ERCC1和TUBB3表达对接受一线铂类-紫杉醇化疗的晚期非小细胞肺癌（NSCLC）患者的预测价值。
Cancer Chemother Pharmacol. 2014 Oct;74(4):777-86. doi: 10.1007/s00280-014-2562-1. Epub 2014 Aug 9.
7
Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.切除修复交叉互补基因 1 蛋白作为铂类为基础的一线化疗治疗晚期非小细胞肺癌患者的预后因素。
Lung Cancer. 2013 Nov;82(2):324-9. doi: 10.1016/j.lungcan.2013.08.001. Epub 2013 Aug 11.
8
Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.非小细胞肺癌中铂类化疗的药物遗传学：ERCC1基因多态性的预测效度
Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):17-24. doi: 10.1080/17425255.2018.1416095. Epub 2017 Dec 18.
9
Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.ERCC1-C118T 和 -C8092A 多态性与接受铂类化疗的晚期非小细胞肺癌患者的肺癌风险和生存的关联：基于 39 份报告的汇总分析。
Gene. 2013 Sep 10;526(2):265-74. doi: 10.1016/j.gene.2013.05.021. Epub 2013 May 30.
10
[Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].[ERCC1 mRNA表达在接受铂类化疗的非小细胞肺癌患者中的预后意义]
Zhonghua Zhong Liu Za Zhi. 2009 Jan;31(1):33-7.

引用本文的文献

1
Small Molecule Antagonists of the DNA Repair ERCC1/XPA Protein-Protein Interaction.DNA 修复 ERCC1/XPA 蛋白-蛋白相互作用的小分子拮抗剂。
ChemMedChem. 2024 Apr 16;19(8):e202300648. doi: 10.1002/cmdc.202300648. Epub 2024 Mar 5.
2
DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort study.DNA损伤修复基因突变预测晚期非小细胞肺癌铂类化疗及免疫治疗联合铂类化疗的疗效：一项中国回顾性队列研究
Transl Lung Cancer Res. 2022 Dec;11(12):2539-2566. doi: 10.21037/tlcr-22-746.
3
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
用于鉴定同源重组缺陷肿瘤和患者分层的RAD51检测的临床前体内验证
Cancer Res. 2022 Apr 15;82(8):1646-1657. doi: 10.1158/0008-5472.CAN-21-2409.
4
Synergistic effects of olaparib combined with on the sensitivity of cisplatin in non-small cell lung cancer.奥拉帕利联合[未提及药物名称]对非小细胞肺癌顺铂敏感性的协同作用。
Oncol Lett. 2021 May;21(5):365. doi: 10.3892/ol.2021.12626. Epub 2021 Mar 10.
5
Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts.ERCC1、XPF和DNA聚合酶β表达对患者来源的卵巢癌异种移植模型中铂类药物反应的影响
Cancers (Basel). 2020 Aug 24;12(9):2398. doi: 10.3390/cancers12092398.
6
Excision repair of topoisomerase DNA-protein crosslinks (TOP-DPC).拓扑异构酶 DNA-蛋白质交联（TOP-DPC）的切除修复。
DNA Repair (Amst). 2020 May;89:102837. doi: 10.1016/j.dnarep.2020.102837. Epub 2020 Mar 7.
7
Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study.低 ERCC1 表达是所有 TNM 分期的肺腺癌患者接受基于铂类化疗的良好预测标志物：一项单中心研究。
Diagn Pathol. 2019 Sep 14;14(1):105. doi: 10.1186/s13000-019-0885-2.
8
AC138128.1 an Intronic lncRNA originating from ERCC1 Implies a Potential Application in Lung Cancer Treatment.AC138128.1，一种源自ERCC1的内含子长链非编码RNA，提示其在肺癌治疗中的潜在应用。
J Cancer. 2019 Jun 9;10(16):3608-3617. doi: 10.7150/jca.31832. eCollection 2019.
9
Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.胞苷脱氨酶酶活性是吉西他滨/铂类治疗晚期非小细胞肺癌的预后生物标志物：一项前瞻性验证研究。
Br J Cancer. 2018 Nov;119(11):1326-1331. doi: 10.1038/s41416-018-0307-3. Epub 2018 Nov 8.
10
Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?免疫组织化学在肺癌患者治疗预测生物标志物中能占据一席之地吗？
Cancers (Basel). 2018 Mar 13;10(3):70. doi: 10.3390/cancers10030070.